1256580-46-7 | 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$63.00	$45.00
250mg	95%	in stock	$66.00	$47.00
1g	95%	in stock	$187.00	$131.00
5g	95%	in stock	$573.00	$402.00
10g	95%	in stock	$946.00	$662.00
25g	95%	in stock	$1,879.00	$1,316.00

Description

• Catalog Number: AA31245
• Chemical Name: 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
• CAS Number: 1256580-46-7
• Molecular Formula: C30H34N4O2
• Molecular Weight: 482.6166
• MDL Number: MFCD19440988
• SMILES: CCc1cc2C(=O)c3c4ccc(cc4[nH]c3C(c2cc1N1CCC(CC1)N1CCOCC1)(C)C)C#N

Computed Properties

• Complexity: 867
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 5.2

Literature

• Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

  Toxicology letters 20180701

• 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells.

  Chemico-biological interactions 20180325

• ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.

  Therapeutic advances in medical oncology 20160101

• Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.

  Drugs 20150101

• Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20141115

• Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20141115

• Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.

  Cancer letters 20140901

• Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).

  Bioorganic & medicinal chemistry 20120201

• CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

  Cancer cell 20110517

• KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090501

• Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

  Nature 20070802